Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Biomarkers of response to ocrelizumab in relapsing-remitting multiple sclerosis.
Rodríguez-Jorge F, Fernández-Velasco JI, Villarrubia N, Gracia-Gil J, Fernández E, Meca-Lallana V, Díaz-Pérez C, Sainz de la Maza S, Pacheco EM, Quiroga A, Ramió-Torrentà L, Martínez-Yélamos S, Bau L, Monreal E, López-Real A, Rodero-Romero A, Borrega L, Díaz S, Eguía P, Espiño M, Chico-García JL, Barrero FJ, Martínez-Ginés ML, García-Domínguez JM, De la Fuente S, Moreno I, Sainz-Amo R, Mañé-Martínez MA, Caminero A, Castellanos F, Gómez López A, Labiano-Fontcuberta A, Ayuso L, Abreu R, Hernández MÁ, Meca-Lallana J, Martín-Aguilar L, Muriel García A, Masjuan J, Costa-Frossard L, Villar LM. Rodríguez-Jorge F, et al. Among authors: meca lallana v. Front Immunol. 2024 Nov 12;15:1480676. doi: 10.3389/fimmu.2024.1480676. eCollection 2024. Front Immunol. 2024. PMID: 39606235 Free PMC article.
Observational study of gadolinium-enhancing lesions in MRI in patients with multiple sclerosis from the Spanish Mediterranean coast: Seasonal variability and relationship with climatic factors.
Romero Del Rincón C, Claramonte-Clausell B, Aguirre C, Domiguez-Gallego M, Meca-Lallana V, Belenguer Benavides A. Romero Del Rincón C, et al. Among authors: meca lallana v. Mult Scler Relat Disord. 2024 Dec;92:106164. doi: 10.1016/j.msard.2024.106164. Epub 2024 Nov 10. Mult Scler Relat Disord. 2024. PMID: 39571217
Beyond lines of treatment: embracing early high-efficacy disease-modifying treatments for multiple sclerosis management.
Oreja-Guevara C, Martínez-Yélamos S, Eichau S, Llaneza MÁ, Martín-Martínez J, Peña-Martínez J, Meca-Lallana V, Alonso-Torres AM, Moral-Torres E, Río J, Calles C, Ares-Luque A, Ramió-Torrentà L, Marzo-Sola ME, Prieto JM, Martínez-Ginés ML, Arroyo R, Otano-Martínez MÁ, Brieva-Ruiz L, Gómez-Gutiérrez M, Rodríguez-Antigüedad A, Galán Sánchez-Seco V, Costa-Frossard L, Hernández-Pérez MÁ, Landete-Pascual L, González-Platas M, Meca-Lallana JE. Oreja-Guevara C, et al. Among authors: meca lallana v. Ther Adv Neurol Disord. 2024 Oct 16;17:17562864241284372. doi: 10.1177/17562864241284372. eCollection 2024. Ther Adv Neurol Disord. 2024. PMID: 39483817 Free PMC article. Review.
Real-World Experience with Diroximel Fumarate in Patients with Multiple Sclerosis: A Prospective Multicenter Study.
Aguirre C, Alonso-Torres A, Agüera E, García-Domínguez JM, Montero-Escribano P, González-Quintanilla V, Costa-Frossard L, Oreja-Guevara C, Reyes-Garrido V, Caminero-Rodríguez AB, Riancho J, Sánchez O, Forero L, Pérez-Parra F, Ares-Luque A, Téllez N, Arzalluz-Luque J, Iglesias F, Casado-Ruiz V, Castellano-Vicente AJ, Borrega L, Galán V, de Antonio LAR, Romero C, García-Rodríguez R, Cano-Orgaz AT, Sánchez-Menoyo JL, Pérez-Ruiz D, Gutiérrez-Martin F, Hernández-Echevarría L, Meca-Lallana V. Aguirre C, et al. Among authors: meca lallana v. Clin Drug Investig. 2024 Nov;44(11):829-838. doi: 10.1007/s40261-024-01397-5. Epub 2024 Oct 28. Clin Drug Investig. 2024. PMID: 39466585
Does serum neurofilament light chain measurement influence therapeutic decisions in multiple sclerosis?
Saposnik G, Monreal E, Medrano N, García-Domínguez JM, Querol L, Meca-Lallana JE, Landete L, Salas E, Meca-Lallana V, García-Arcelay E, Agüera-Morales E, Martínez-Yélamos S, Gómez-Ballesteros R, Maurino J, Villar LM, Caminero AB. Saposnik G, et al. Among authors: meca lallana v. Mult Scler Relat Disord. 2024 Oct;90:105838. doi: 10.1016/j.msard.2024.105838. Epub 2024 Aug 23. Mult Scler Relat Disord. 2024. PMID: 39216454
Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: DISCOVER study.
Oreja-Guevara C, Meca-Lallana JE, Díaz-Díaz J, Ara JR, Hernández Pérez MÁ, Gracia Gil J, Alonso Torres AM, Pilo de la Fuente B, Ramió-Torrentà L, Eichau Madueño S, Gascón-Giménez F, Casanova B, Martínez-Yélamos S, Aguado Valcárcel M, Martínez Ginés ML, El Berdei Montero Y, López Real AM, González-Quintanilla V, De Torres L, Martínez-Rodríguez JE, Costa-Frossard L, Garcés Redondo M, Labiano Fontcuberta A, Castellanos-Pinedo F, García Merino JA, Muñoz Fernández C, Castillo-Triviño T, Meca-Lallana V, Peña Martínez J, Rodríguez-Antigüedad A, Prieto González JM, Agüera Morales E, Pérez Molina I, Solar Sánchez DM, Herrera Varo N, Romero Sevilla R, Gómez Vicente L, Río J. Oreja-Guevara C, et al. Among authors: meca lallana v. Mult Scler Relat Disord. 2024 Oct;90:105787. doi: 10.1016/j.msard.2024.105787. Epub 2024 Aug 2. Mult Scler Relat Disord. 2024. PMID: 39142050 Free article.
[XVI Post-ECTRIMS Meeting: review of the new developments presented at the 2023 ECTRIMS Congress (II)].
Fernández O, Montalbán X, Agüera E, Aladro Y, Alonso A, Arroyo R, Brieva L, Calles C, Costa-Frossard L, Eichau S, García-Domínguez JM, Hernández MA, Landete L, Llaneza M, Llufriu S, Meca-Lallana JE, Meca-Lallana V, Moral E, Prieto JM, Ramió-Torrentà L, Téllez N, Romero-Pinel L, Vilaseca A, Rodríguez-Antigüedad A. Fernández O, et al. Among authors: meca lallana v. Rev Neurol. 2024 Jul 16;79(2):51-66. doi: 10.33588/rn.7902.2024174. Rev Neurol. 2024. PMID: 38976584 Free PMC article. Spanish.
[XVI Post-ECTRIMS Meeting: review of the new developments presented at the 2023 ECTRIMS Congress (I)].
Fernández O, Montalbán X, Agüera E, Aladro Y, Alonso A, Arroyo R, Brieva L, Calles C, Costa-Frossard L, Eichau S, García-Domínguez JM, Hernández MA, Landete L, Llaneza M, Llufriu S, Meca-Lallana JE, Meca-Lallana V, Moral E, Prieto JM, Ramió-Torrentà L, Téllez N, Romero-Pinel L, Vilaseca A, Rodríguez-Antigüedad A. Fernández O, et al. Among authors: meca lallana v. Rev Neurol. 2024 Jul 1;79(1):21-29. doi: 10.33588/rn.7901.2024170. Rev Neurol. 2024. PMID: 38934946 Free PMC article. Review. Spanish.
Real-World Retrospective Analysis of Alemtuzumab Outcomes in Relapsing-Remitting Multiple Sclerosis: The LEMCAM Study.
Costa-Frossard França L, Meca Lallana V, Labiano-Fontcuberta A, Blasco R, Monreal E, Martínez Ginés ML, Aguirre C, Sabin Muñoz J, Sainz de la Maza S, Cuello JP, Díaz-Pérez C, Chico García JL, Lozano Ros A, Rodríguez Jorge F, Martínez Martínez S, García Domínguez JM. Costa-Frossard França L, et al. Among authors: meca lallana v. CNS Drugs. 2024 Mar;38(3):231-238. doi: 10.1007/s40263-024-01066-3. Epub 2024 Feb 28. CNS Drugs. 2024. PMID: 38418770 Free PMC article.
Defining a standard set of health outcomes for patients with relapsing-remitting multiple sclerosis.
Llaneza González M, Carrascal Rueda P, Delgado Sánchez O, Borges Guerra M, Rodríguez Antigüedad A, Morell Baladrón A, Becerril Ríos N, Rovira À, Meca Lallana V, Benedito-Palos L, Comellas M, Vilanova D, Echeto A, Pérez X, Oreja-Guevara C. Llaneza González M, et al. Among authors: meca lallana v. Mult Scler Relat Disord. 2024 Apr;84:105501. doi: 10.1016/j.msard.2024.105501. Epub 2024 Feb 13. Mult Scler Relat Disord. 2024. PMID: 38401203 Free article. Review.
68 results